Canine and feline haemangiosarcoma

Vet Rec. 2021 Nov;189(9):e585. doi: 10.1002/vetr.585. Epub 2021 Jul 2.

Abstract

Introduction: Haemangiosarcoma (HSA) is a malignant neoplasm of dogs and cats that is suspected to originate from a pluripotent bone marrow progenitor with a complex and multifactorial pathogenesis.

Approach: Pertinent literature was identified, reviewed, and summarized for inclusion in the manuscript.

Results/interpretation: Dogs are more frequently diagnosed with HSA than cats, and primary sites of this disease include dermal, subcutaneous/intramuscular, and visceral (most commonly the spleen). Dogs and cats with HSA generally have a poor prognosis owing to the rapid and widespread metastasis typically associated with this disease. However, some forms such as cutaneous HSA behave in a less aggressive fashion with improved outcomes. Surgical excision and anthracycline-based chemotherapy remain the mainstays of treatment, although novel treatment modalities are currently under investigation for potential roles in treatment of this disease.

Conclusion: This review aims to describe the clinical presentation and progression of the various forms of HSA in dogs and cats as well as to provide a systematic review of the veterinary literature with a focus on the various published treatment options and associated outcomes.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Cat Diseases* / diagnosis
  • Cat Diseases* / epidemiology
  • Cat Diseases* / therapy
  • Cats
  • Dog Diseases* / diagnosis
  • Dog Diseases* / drug therapy
  • Dog Diseases* / epidemiology
  • Dogs
  • Hemangiosarcoma* / diagnosis
  • Hemangiosarcoma* / therapy
  • Hemangiosarcoma* / veterinary